ACEIs and ARBs and Their Correlation with COVID-19: A Review

Awgichew Shewasinad Yehualashet; Teshome Fentik Belachew

doi:10.2147/IDR.S264882

ACEIs and ARBs and Their Correlation with COVID-19: A Review

Infect Drug Resist. 2020 Sep 16:13:3217-3224. doi: 10.2147/IDR.S264882. eCollection 2020.

Authors

Awgichew Shewasinad Yehualashet¹, Teshome Fentik Belachew²

Affiliations

¹ Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
² Department of Pharmacy, Debre Birhan Health Science College, Debre Birhan, Ethiopia.

Abstract

Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.

Keywords: ACEIs; ARBs; COVID-19; coronavirus.

Publication types

Review